Claims for Patent: 7,914,783

Summary for Patent: 7,914,783

Title:	Pharmacological vitreolysis
Abstract:	Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
Inventor(s):	Pakola; Steve (Sleepy Hollow, NY), De Smet; Marc (Amstelveen, NL)
Assignee:	ThromboGenics NV (Heverlee, BE)
Application Number:	11/786,354
Patent Claims:	1. A method of liquefying a vitreous and/or inducing posterior vitreous detachment of an eye of a subject who is at a risk of developing vitreomacular traction, a macular hole, retinal detachment, a retinal tear, retinal neovascularization, retinal hemorrhage, or macular edema, as a complication of a disorder or of incomplete posterior vitreous detachment of an eye of the subject, comprising contacting a vitreous and/or an aqueous humor in the eye of the subject with an effective amount of a composition comprising microplasmin, wherein the method results in liquefying a vitreous and/or inducing posterior vitreous detachment of the eye of the subject. 2. The method of claim 1, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin. 3. The method of claim 1, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor. 4. The method of claim 1, wherein the subject is a human. 5. The method of claim 1, wherein the method is a prophylactic method. 6. The method of claim 1, wherein the method is performed in the absence of mechanical vitrectomy. 7. The method of claim 1, wherein the method is performed as an adjunct to vitrectomy. 8. The method of claim 1, wherein the method is performed prior to mechanical vitrectomy. 9. The method of claim 1, wherein an effective amount of a dose of microplasmin is in the range of 0.005 mg to 0.2 mg per eye. 10. A method of preventing development of vitreomacular traction, a macular hole, retinal detachment, a retinal tear, retinal neovascularization, retinal hemorrhage, or macular edema, as a complication of a disorder or of incomplete posterior vitreous detachment of an eye of a subject, comprising contacting a vitreous and/or an aqueous humor in the eye of the subject with an effective amount of a composition comprising microplasmin, wherein the method results in vitreous liquefaction and/or posterior vitreous detachment in the eye of the subject. 11. The method of claim 10, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin. 12. The method of claim 10, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor. 13. The method of claim 10, wherein the subject is a human. 14. The method of claim 10, wherein the method is performed in the absence of mechanical vitrectomy. 15. The method of claim 10, wherein the method is performed as an adjunct to vitrectomy. 16. The method of claim 10, wherein the method is performed prior to mechanical vitrectomy. 17. The method of claim 10, wherein an effective amount of a dose of microplasmin is in the range of 0.005 mg to 0.2 mg per eye. 18. A method of delaying the onset or reducing the incidence of a disorder of an eye of a subject, wherein the disorder is associated with vitreous contraction or neovascularization into the vitreous, comprising contacting a vitreous and/or aqueous humor in the eye of the subject with an effective amount of a composition comprising microplasmin, wherein the method results in vitreous liquefaction and/or posterior vitreous detachment in the eye of the subject, thereby delaying the onset or reducing the incidence of the disorder. 19. The method of claim 18, wherein the disorder associated with vitreous contraction is retinal detachment, a retinal tear, or retinal hemorrhage. 20. A method of inhibiting a complication in central or branch retinal vein occlusion of an eye of a subject, comprising contacting a vitreous and/or aqueous humor in the eye of the subject with an effective amount of a composition comprising microplasmin, wherein the method results in vitreous liquefaction and/or posterior vitreous detachment in the eye of the subject, thereby inhibiting a complication in central or branch retinal vein occlusion. 21. The method of claim 20, wherein the complication is retinal neovascularization or macular edema.

Details for Patent 7,914,783

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	February 22, 2017		2022-12-06
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	October 17, 2012		2022-12-06

International Patent Family for US Patent 7,914,783

Country	Patent Number	Estimated Expiration
South Africa	200505193
World Intellectual Property Organization (WIPO)	2004052228
United States of America	9770494